Low-dose Erythropoietin reduces risk of heart failure induced by anti-cancer therapy

Oncotarget. 2011 Nov;2(11):825. doi: 10.18632/oncotarget.352.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects*
  • Erythropoietin / pharmacology*
  • Heart Failure / chemically induced*
  • Heart Failure / prevention & control*
  • Humans
  • Risk

Substances

  • Antineoplastic Agents
  • Erythropoietin